Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Radiotherapy Consolidation Reduces Risk of Relapse in Diffuse Large B-Cell Lymphoma Patients with Bulky Disease in Complete Response after Frontline Immunochemotherapy: Results from a Retrospective Single Center Study

Corrado Benevolo Savelli, Mattia Novo, Francesco Vassallo, Andrea Evangelista, Matteo Bisio, Luca Legato, Veronica Peri, Michele Clerico, Mario Levis, Sara Bartoncini, Chiara Cavallin, Maura Nicolosi, Carola Boccomini, Lorella Orsucci, Federica Cavallo, Benedetto Bruno, Roberto Freilone, Umberto Ricardi, Barbara Botto

Blood (2023) 142 (Supplement 1): 4484.

https://doi.org/10.1182/blood-2023-184510

Published: 2023

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Emanuele Zucca, Luca Ceriani, Andrew S. Davies, Giovannino Ciccone, Umberto Ricardi, Alice Di Rocco, Iryna Kryachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Sara Usai, Luca Arcaini, Elsa Pennese, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Franceso Merli, Wei Li Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Stefano Volpetti, Carla Minoia, Michele Spina, Alexander Fossa, George Mikhaeel, Kate Cwynarski, Andrea Janikova, Yana Stepanishyna, Mats Jerkeman, Andreas Huettmann, Maria Gomes da Silva, Don A. Stevens, Sally F Barrington, Bogdan Małkowski, Ur Metser, Annibale Versari, Stephane Chauvie, Oreste Bagni, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Letizia Deantonio, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Franco Cavalli, Peter Johnson, Maurizio Martelli

Blood (2023) 142 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2023-174093

Published: 2023

Journal Articles

PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Blood (2022) 140 (Supplement 1): 1765–1767.

https://doi.org/10.1182/blood-2022-159759

Published: 2022

Journal Articles

Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG

Blood (2020) 135 (26): 2365–2374.

https://doi.org/10.1182/blood.2019003877

Published: 2020

Includes: Supplemental data

Journal Articles

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Joachim Yahalom, Bouthaina Shbib Dabaja, Umberto Ricardi, Andrea Ng, N. George Mikhaeel, Ivan R. Vogelius, Tim Illidge, Shunan Qi, Andrew Wirth, Lena Specht

Blood (2020) 135 (21): 1829–1832.

https://doi.org/10.1182/blood.2020006028

Published: 2020

Includes: Supplemental data

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Definitive radiotherapy for localized follicular lymphoma staged by 18 F-FDG PET-CT: a collaborative study by ILROG

Blood (2019) 133 (3): 237–245.

https://doi.org/10.1182/blood-2018-04-843540

Published: 2019

Includes: Supplemental data

Journal Articles

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Blood (2018) 131 (13): 1456–1463.

https://doi.org/10.1182/blood-2017-07-795476

Published: 2018

Includes: Supplemental data

Journal Articles

Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial

Blood (2016) 128 (22): 184.

https://doi.org/10.1182/blood.V128.22.184.184

Published: 2016

Journal Articles

Either Combined-Modality Or Radiotherapy Alone Provide Favorable Outcome In Stage I-II Mantle Cell Lymphoma: A Report Of 82 Patients From The International Lymphoma Radiation Oncology Group (ILROG)

Bouthaina S. Dabaja, MD, Richard Tsang, MD, Shunan Qi, Pamela Allen, PhD, David C. Hodgson, MD, Umberto Ricardi, MD, Richard T. Hoppe, MD, Andrea Ng, Lena Specht, Ye-xiong Li, MD, Stephanie Terezakis, MD, Louis Constine, MD, Joachim Yahalom, MD

Blood (2013) 122 (21): 4292.

https://doi.org/10.1182/blood.V122.21.4292.4292

Published: 2013

Journal Articles

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Marco Ruella, MD, Andrea Filippi, MD, Anna DI Russo, MD, Daniele Caracciolo, MD, Paola Matteucci, MD, Michele Magni, MD, Massimo Di Nicola, MD, Umberto Ricardi, MD, Vittorio Montefusco, MD, Guido Parvis, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD, Liliana Devizzi, MD

Blood (2011) 118 (21): 3699.

https://doi.org/10.1182/blood.V118.21.3699.3699

Published: 2011

Journal Articles

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

Blood (2009) 113 (14): 3375–3382.

https://doi.org/10.1182/blood-2008-07-167379

Published: 2009

Journal Articles

Radioimmunotherapy (RIT) with 90 y-Ibritumomab Tiuxetan (Zevalin) in Relapsed or Refractory Aggressive Lymphoma Previously Treated with Rituximab Containing Regimens

Barbara Botto, Marilena Bellò, Annalisa Chiappella, Roberto Passera, Giulia Benevolo, Carola Boccomini, Maria Giuseppina Cabras, Claudia Castellino, Giuseppe Fioritoni, Chiara Frairia, Roberto Freilone, Maurizio Martelli, Lorella Orsucci, Patrizia Pregno, Paola Scapoli, Anna Tonso, Umberto Ricardi, Giovanni Bisi, Umberto Vitolo

Blood (2008) 112 (11): 5014.

https://doi.org/10.1182/blood.V112.11.5014.5014

Published: 2008

Journal Articles

Rituximab (R) in Addition to Dose-Dense Chemotherapy MegaCEOP and Intensification with R-MAD Followed by High Dose Chemotherapy BEAM with Autologous Stem Cell Transplantation (ASCT) Is Safe and Effective in Untreated High Risk Diffuse Large B-Cell Lymphoma (DLBCL).

Annalisa Chiappella, Giuseppe Rossi, Maria Giuseppina Cabras, Anna Marina Liberati, Giovannino Ciccone, Flavia Salvi, Emanuele Angelucci, Barbara Botto, Antonella Darbesio, Roberto Freilone, Lorella Orsucci, Vincenzo Pavone, Enrico Maria Pogliani, Umberto Ricardi, Delia Rota-Scalabrini, Anna Tonso, Alessandra Tucci, Eugenio Gallo, Umberto Vitolo

Blood (2007) 110 (11): 1899.

https://doi.org/10.1182/blood.V110.11.1899.1899

Published: 2007

NARROW

Radiotherapy Consolidation Reduces Risk of Relapse in Diffuse Large B-Cell Lymphoma Patients with Bulky Disease in Complete Response after Frontline Immunochemotherapy: Results from a Retrospective Single Center Study

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Definitive radiotherapy for localized follicular lymphoma staged by 18 F-FDG PET-CT: a collaborative study by ILROG

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial

Either Combined-Modality Or Radiotherapy Alone Provide Favorable Outcome In Stage I-II Mantle Cell Lymphoma: A Report Of 82 Patients From The International Lymphoma Radiation Oncology Group (ILROG)

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

Radioimmunotherapy (RIT) with 90 y-Ibritumomab Tiuxetan (Zevalin) in Relapsed or Refractory Aggressive Lymphoma Previously Treated with Rituximab Containing Regimens

Rituximab (R) in Addition to Dose-Dense Chemotherapy MegaCEOP and Intensification with R-MAD Followed by High Dose Chemotherapy BEAM with Autologous Stem Cell Transplantation (ASCT) Is Safe and Effective in Untreated High Risk Diffuse Large B-Cell Lymphoma (DLBCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only